[**Numeric Identifier 47969**]  Admission Date:  [**2103-6-11**]       Discharge Date:  [**2103-7-27**]  Date of Birth:   [**2103-6-11**]       Sex:  M  Service: Neonatology  HISTORY OF PRESENT ILLNESS:  Infant is a 2045 gram, 32 week, male newborn, admitted to the Neonatal Intensive Care Unit for management of prematurity.
PRIOR MATERNAL OBSTETRIC HISTORY:  Previous cesarean section, followed by two VBACs.
At 24 weeks, mother was admitted to [**Hospital1 69**] for expectant management with some concern for extension of dehiscence.
Mother received betamethasone at 24 weeks and 30 weeks gestation.
Decision was made to deliver the infant by cesarean section at 32 weeks gestation.
Infant was placed on CPAP and received 25 to 30% FI02.
Infant was noted to have increased respiratory distress on day of life two, was intubated and received two doses of surfactant.
He was extubated on day of life two to CPAP and weaned to nasal cannula by day of life three.
Caffeine was started on day of life 13 for increased apnea and bradycardia and was discontinued on day of life 20.
Infant was started on enteral feedings on day of life two and advanced to full volume feedings by day of life seven.
Infant tolerated feeding advancement without difficulties.
Calories were eventually decreased for growth and the infant is currently receiving minimum of 130 cc per kg per day of breast milk or Enfamil 20 calories per ounce.
GASTROINTESTINAL:  Infant received single phototherapy from day of life four to day of life five; maximum bilirubin level of 12.2 with a direct of 0.3.
HEMATOLOGY:  Infant did not receive any blood transfusions this hospitalization.
He is being discharged home on iron supplementation due to his prematurity.
INFECTIOUS DISEASE: Infant received 48 hours of ampicillin and gentamicin for rule out sepsis.
OPHTHALMOLOGY:  Infant did not meet criteria for eye examination.
minimum 130 cc per kg per day.
Polyvisol 1 cc po daily.
IMMUNIZATIONS:  Infant received hepatitis B vaccine on [**2103-6-23**].
IMMUNIZATIONS RECOMMENDED:  Synagis-RSV prophylaxis should be considered from [**Month (only) 359**] through [**Month (only) 547**] for infants who meet any of the following three criteria: 1.)
Status post indirect hyperbilirubinemia.
